Cost-utility analysis and budget impact analysis of pegvisomant for the treatment of adult patients with acromegaly in Poland
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2018, Vol 2, Issue 2
Abstract
Background: The aim of this publication was to evaluate the cost-effectiveness and financial consequences of pegvisomant (PEG) in the treatment of adult patients with acromegaly, who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues (SSA) did not normalize IGF-1 concentrations or was not tolerated compared with SSA continuation. Methods: The Markov model constructed in TreeAge Pro with 45-year time horizon was used in the cost-utility analysis (CUA). Quality adjusted life years (QALY) were used as the measure of effectiveness. CUA was conducted from the perspective of the public payer for health services (Polish National Health Fund, PNHF) and from the patient’s and PNHF’s perspective. Budget impact analysis was performed in a 3-year time horizon from PNHF’s perspective. Two scenarios were compared: “present”, without reimbursement of PEG; “new”, after reimbursement of PEG. Results: The cost of gaining an additional QALY by replacing SSA with PEG is equal 742,724 PLN/ 714,800 PLN (172 470 €/ 165 986 €) from PNHF/PNHF+patient perspective. The annual expenditure of the PNHF’s budget in the first three years would increase by approximately 11.95 million PLN in the first, 26.39 million PLN in the second and 26.5 million in the third year of PEG reimbursement. Conclusion: The creation of drug program for acromegalic patients, in which reimbursement of PEG will be provided, will significantly influence the prognosis, course of the disease and improve the patient’s quality of life.
Authors and Affiliations
Ewa Borowiack, Magdalena Marzec, Anna Nowotarska, Katarzyna Policht, Małgorzata Konopka-Pliszka, Joanna Jarosz, Monika Borowiack
Keywords
Related Articles
- EP ID EP532140
- DOI 10.7365/JHPOR.2018.2.3
- Views 44
- Downloads 0
The study of the need for interprofessional collaboration in the health care system in Poland - experience of Lesław A. Paga Foundation.
Background: Interprofessional collaboration (IC) in healthcare is a process by which professionals from different disciplines collaborate to provide an integrated and cohesive approach to patient care. The Lesław A. Paga...
Mepolizumab: a new drug programme for patients with severe eosinophilic asthma
Biological treatment involves more and more fields of medicine. This also applies to severe asthma for which a therapy with omalizumab (anti-IgE antibodies for patients with allergic asthma) has been available since 2013...
Budget impact analysis of breast cancer in the Russian Federation
Breast cancer is one of the leading causes of cancer-related morbidity and mortality in the female population of the Russia and its incidence is rapidly growing. Advanced breast cancer is a disease currently intreatable,...
Treatment and prevention of bleeding in adult hemophilia A patients with inhibitor – economic analysis.
Hemophilia A is caused by an absence or deficiency of coagulation factor VIII. Patients with hemophilia may experience recurrent spontaneous hemarthroses or internal bleeding. Following the treatment with factor VIII con...
Is the cost-effectiveness threshold cost-effective in cancer therapy?
Introduction: To compare availability of innovative cancer drugs in countries with established cost-effectiveness threshold (Great Britain, Czech Republic, Sweden and Poland) and where this criterion is not used (Germany...